Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2010; 103(04): 855-856
DOI: 10.1160/TH09-10-0687
DOI: 10.1160/TH09-10-0687
Letters to the Editor
The in vitro response to low-molecular-weight heparin is not age-dependent in children
Further Information
Publication History
Received:
05 October 2009
Accepted after major revision:
10 February 2009
Publication Date:
22 November 2017 (online)
-
References
- 1 Monagle P, Chalmers E, Chan A. et al. Antithrombotic therapy in neonates and children. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (Suppl. 06) 887S-968S.
- 2 Bauman ME, Belletrutti MJ, Bajzar L. et al. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels. Thromb Haemost 2009; 101: 86-92.
- 3 Dix D, Andrew M, Marzinotto V. et al. The use of low molecular weight heparin in pediatric patients : A prospective cohort study. J Paeds 2000; 136: 439-445.
- 4 Kuhle S, Massicotte P, Dinyari M. et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005; 94: 1164-1171.
- 5 Massicotte P, Adams M, Marzinotto V. et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996; 128: 313-318.
- 6 Massicotte P, Julian J, Gent M. et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003; 109: 101-108.
- 7 Ignjatovic V, Furmedge J, Newall F. et al. Age-related differences in heparin response. Thromb Res 2006; 118: 741-745.
- 8 Monagle P, Barnes C, Ignjatovic V. et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95: 362-372.
- 9 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
- 10 Baier K, Cvirn G, Fritsch P. et al. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma. Ped Res 2005; 57: 685-689.
- 11 Cvirn G, Cimenti C, Kutschera J. et al. Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT). Eur J Pediatr 2007; 166: 427-431.
- 12 Depassea F, González de Susob MJ, Lagouttec I. et al. Comparative study of the pharmacokinetic profiles of two LMWHs—bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa) administered subcutaneously to healthy male volunteers. Thromb Res 2003; 109: 109-117.
- 13 Hirsh J. Low molecular weight heparin. Thromb Haemost 1993; 70: 204-207.